National Cholesterol Education Program and ATP III Guidelines Overview

Introduction to High Cholesterol and CHD

  • Approximately 65 million Americans have high cholesterol; 37 million require therapy.

  • Cardiovascular disease is the leading cause of death, with a strong correlation between serum cholesterol levels and mortality from coronary artery disease (CAD).

  • No threshold level for cholesterol was identified; risk is progressive with increased levels.

  • ATP III guidelines released in 2002 by NHLBI focus on detecting, evaluating, and treating high cholesterol linked to CHD.

Background of NCEP and ATP III Guidelines

  • Established in 1985 to develop practice guidelines for identifying and treating high cholesterol to reduce CHD risk.

  • Expert panels created recommendations for clinical practice and standardization of lipid measurement.

  • Treatments focus on LDL-C but now also address lifestyle changes and expanding therapy indications.

  • Updated guidelines (2013) aimed at comprehensive assessment and management including obesity and lifestyle.

CHD Risk Equivalents and Multiple Risk Factors

  • Common risk factors: diabetes mellitus or multiple risk factors confer > 20% ten-year CHD risk; require aggressive treatment.

  • Framingham Heart Study used for risk estimation, determining CHD risk using age, gender, TC, HDL-C, blood pressure, and smoking status.

  • The ACC/AHA guidelines present new quantitative risk assessment calculators.

Metabolic Syndrome X

  • Defined by the presence of three or more disorders related to metabolism.

  • Risk factors include:

    • Abdominal obesity (waist circumference ≥ 40" for men, ≥ 35" for women).

    • High blood pressure (systolic > 130 mmHg or diastolic > 85 mmHg).

    • High blood sugar (fasting glucose > 100 mg/dL).

    • Insulin resistance and lipid abnormalities (high triglycerides, low HDL-C).

Therapeutic Lifestyle Changes (TLC)

  • Emphasizes dietary changes to reduce saturated fats (<7% total calories) and cholesterol (<200 mg/day).

  • Weight reduction and physical activity also integral to reducing LDL-C and CHD risk.

Fasting Lipid Profiles

  • Recommended initial screening uses a fasting lipid panel every 5 years.

  • Validity of tests post-acute coronary events requires testing within 24 hours.

LDL-C Cut Points

  • Revised medical decision values:

    • Optimal: < 100 mg/dL (2.58 mmol/L)

    • Near Optimal: 100-129 mg/dL (2.58–3.33 mmol/L)

    • Borderline High: 130-159 mg/dL (3.36–4.11 mmol/L)

    • High: 160-189 mg/dL (4.13–4.88 mmol/L)

    • Very High: > 190 mg/dL (4.91 mmol/L)

Triglycerides Cut Points

  • Revised cut points:

    • Normal: < 150 mg/dL (1.70 mmol/L)

    • Borderline High: 150-199 mg/dL (1.70-2.25 mmol/L)

    • High: 200-499 mg/dL (2.26-5.64 mmol/L)

    • Very High: > 500 mg/dL (5.65 mmol/L)

Non-HDL-C Calculation

  • Non-HDL-C = Total Cholesterol - HDL-C; important for assessing atherogenic risks and is treated as a secondary target when LDL-C goals are met yet triglycerides remain elevated.

HDL-C Cut Points

  • Risk category for low HDL-C increased from 35 to 40 mg/dL (0.90 to 1.03 mmol/L).

  • HDL-C > 60 mg/dL (1.55 mmol/L) is a negative risk factor.

Accuracy and Standardization of Measurements

  • Proper classification requires accurate measurement of TC, HDL-C, LDL-C, rising focus on quality tests (CDC standards).

  • CRMLN ensures laboratory calibration accuracy and standardization for reliable lipid testing.

2013 ACC/AHA Guidelines Changes

  • Introduced a new risk calculator integrating diverse population studies including female and African-American data.

  • High-risk groups identified for personalized statin therapy based on LDL-C levels and risk assessments.

Role of Laboratory in Emerging Markers

  • Laboratories should be able to measure new biochemical markers like lipoprotein (a), homocysteine, and C-reactive protein, with increasing relevance as understanding of CHD risk evolves.

Summary

  • ATP III and ACC/AHA guidelines continue promoting reduced morbidity/mortality from CHD and addressing diabetes/metabolic syndrome.

  • Education of medical professionals and the public is crucial for the successful implementation of these guidelines.